Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study

Autor: L N Igwemezie, Marc Bonnay, J.P. Armand, D Abigerges, B Winograd, L Schacter, M. de Forni, Guy G. Chabot, C Terret, Sanjeev Kaul, J Ropers

Publikováno v: Journal of Clinical Oncology. 14:2020-2030

PURPOSE The purpose of this study was to determine the bioavailability (F) of etoposide (E;VP-16) after oral administration of the water-soluble prodrug etoposide phosphate (EP;BMY-40481) during a phase I trial in cancer patients. PATIENTS AND METHOD

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0901ce7759cd7bca4d948654e68d1ac1
https://doi.org/10.1200/jco.1996.14.7.2020

Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies

Autor: B. Winograd, H.E. Gall, W.W. ten Bokkel Huinink, G. Schwartsmann, W.J.F. van der Vijgh, H.M. Pinedo, Pierre Dodion, G. Simonetti, Jan B. Vermorken, J. Joggi, M.B. van Hennik, Nadine Crespeigne

Publikováno v: Cancer Chemotherapy and Pharmacology, 25, 345-351. Springer Verlag
Schwartsmann, G, Dodion, P, Vermorken, J B, ten Bokkel Huinink, W W, Joggi, J, Winograd, B, Gall, H, Simonetti, G, van der Vijgh, W J F, van Hennik, M B, Crespeigne, N & Pinedo, H M 1990, ' Phase I study of Brequinar sodium (NSC368390) in patients with solid malignancies ', Cancer Chemotherapy and Pharmacology, vol. 25, pp. 345-351 .

Brequinar sodium (DUP 785, NSC 368390) is a novel quinoline-carboxylic acid derivative that has been selected for clinical evaluation because of its broad spectrum of antitumor activity in animal models and its novel chemical structure. This compound

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c68e543633c1462decc1aa3082625b2
https://doi.org/10.1007/bf00686235

Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors

Autor: M de Boer-oennert, A. S. T. Planting, B Winograd, Mel Van der Burg, Jhm Schellens, G. Stoter, Jaap Verweij

Publikováno v: Anti-Cancer Drugs, 10, 821-827. Lippincott Williams & Wilkins

BMS-181174, a new mitomycin C (MMC) analog, showed more activity than the parent compound in tumor xenografts. In a phase I study with a 5-30 min slow bolus administration, hematologic and vascular toxicity were observed as major side effects. A prol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::602e54943b5e9ab628efeab2772af508
https://pubmed.ncbi.nlm.nih.gov/10587292

Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide

Autor: Nh Mulder, S Kaul, RS deJong, Dt Sleijfer, Hjm Groen, Ege Devries, Phb Willemse, Wta Vandergraaf, B. Winograd, Dra Uges

Publikováno v: British Jounal of Cancer, 75(11), 1660-1666. Nature Publishing Group
University of Groningen
British Journal of Cancer

Etoposide phosphate is a water-soluble prodrug of etoposide. The plasma pharmacokinetics of etoposide following oral administration of etoposide phosphate or oral etoposide were compared. Seventeen patients with solid tumours were enrolled to receive

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d28a94fbb9b1a2513444a09d150cc2d
https://research.rug.nl/en/publications/f8f9aef4-2aa0-4d7b-83bf-b02a33f84d5c